Photodynamic therapy (PDT) is a treatment for various health disorders, including cancer, that uses a photosensitive agent and light. Unlike other cancer treatments, PDT is a focused treatment that kills cancerous cells without harming the surrounding tissues. When a photosensitive agent is administered, it accumulates in the tumor as it binds to low density lipoproteins. When the tumor is exposed to a specific wavelength of light, the photosensitive agent is activated; this results in the release singlet oxygen, which kills the tumor. The objective of this research was to synthesize and characterize a novel photosensitive agent, H<sub>2</sub>TPP-2A2E. Purification of the novel material was achieved using column chromatography.  In addition, IR, UV-vis, and NMR spectroscopies were used to characterize the product, and purity was determined using HPLC. After determining that our product was refined, cytotoxicity testing in light and dark conditions revealed that the novel H<sub>2</sub>TPP-2A2E, could potentially be used in the next generation of photodynamic therapy.

The creation of a next-generation cancer treatment using photodynamic therapy

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.